Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | BAX | Q07812 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL31008612 | 1.00 | LTA4H (0.47) | LTA4HTSHRCA4KCNA3CA5A | |
| SCHEMBL13289 | 0.97 | LTA4H (0.50) | LTA4HTSHRCA4KCNA3CA5A | |
| SCHEMBL28017927 | 0.97 | LTA4H (0.50) | LTA4HTSHRCA4KCNA3CA5A | |
| SCHEMBL8113527 | 0.94 | LTA4H (0.47) | LTA4HTSHRCA4KCNA3CA5A | |
| SCHEMBL19327377 | 0.94 | LTA4H (0.47) | LTA4HTSHRCA4KCNA3CA5A | |
| SCHEMBL16415989 | 0.94 | LTA4H (0.47) | LTA4HTSHRCA4KCNA3CA5A | |
| Hydrochloric Acid SCHEMBL3848860 | 0.94 | LTA4H (0.47) | LTA4HTSHRCA4KCNA3CA5A | |
| SCHEMBL11679017 | 0.94 | LTA4H (0.47) | LTA4HTSHRCA4KCNA3CA5A | |
| SCHEMBL3009883 | 0.94 | LTA4H (0.47) | LTA4HTSHRCA4KCNA3CA5A | |
| Iodide SCHEMBL11224745 | 0.94 | LTA4H (0.47) | LTA4HTSHRCA4KCNA3CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110117217-B | Preparation method of 1-bromomethyl-2, 3,5, 6-tetrafluoro-4- (trifluoromethyl) benzene | 浙江普洛家园药业有限公司 | 2021-09-28 | — | — | CN | claimed |
| US-6861535-B2 | Cyclization method for the synthesis of pyrrolidine derivative compounds | PPG-SIPSY (FR) | 2005-03-01 | — | — | US | claimed |
| US-20040034235-A1 | Cyclization method for the synthesis of pyrrolidine derivative compounds | PPG-SIPSY, A CORPORATION OF FRANCE (FR) | 2004-02-19 | — | — | US | claimed |
| US-6043371-A | Organic compound synthesis | BALDWIN JACK EDWARD (GB) | 2000-03-28 | — | — | US | claimed |
| EP-0899268-A2 | Process for the preparation of omeprazole and intermediate compounds | Baldwin, Jack Edward (GB) | 1999-03-03 | — | — | EP | claimed |
| CN-110117217-B | Preparation method of 1-bromomethyl-2, 3,5, 6-tetrafluoro-4- (trifluoromethyl) benzene | 浙江普洛家园药业有限公司 | 2021-09-28 | — | — | CN | disclosed |
| CN-110117217-A | Fluoro- 4- (trifluoromethyl) the benzene novel preparation method of 1- bromomethyl -2,3,5,6- four | 横店集团成都分子实验室有限公司 | 2019-08-13 | — | — | CN | disclosed |
| EP-2149563-B9 | NOVEL PYRIMIDINE COMPOUND HAVING DIBENZYLAMINE STRUCTURE, AND MEDICINE COMPRISING THE COMPOUND | KOWA CO (JP) | 2015-04-22 | — | — | EP | disclosed |
| EP-2149563-B1 | NOVEL PYRIMIDINE COMPOUND HAVING DIBENZYLAMINE STRUCTURE, AND MEDICINE COMPRISING THE COMPOUND | KOWA CO (JP) | 2015-01-07 | — | — | EP | disclosed |
| EP-2138489-B9 | NOVEL PYRIMIDINE COMPOUND HAVING BENZYL(HETEROCYCLICMETHYL)AMINE STRUCTURE AND PHARMACEUTICAL PRODUCT CONTAINING THE SAME | KOWA CO (JP) | 2012-10-24 | — | — | EP | disclosed |
| EP-2138489-B1 | NOVEL PYRIMIDINE COMPOUND HAVING BENZYL(HETEROCYCLICMETHYL)AMINE STRUCTURE AND PHARMACEUTICAL PRODUCT CONTAINING THE SAME | KOWA CO (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-20120046308-A1 | NOVEL ALPHA-PHENOXYBENZENEACETIC ACID DERIVATIVE AND PHARMACEUTICAL PREPARATION COMPRISING SAME | KOWA COMPANY, LTD. (JP) | 2012-02-23 | — | — | US | disclosed |
| EP-0015079-B1 | HALOGENATING COMPOUNDS AND A PROCESS FOR THEIR PRODUCTION | ELI LILLY AND COMPANY (US) | 1987-09-09 | — | — | EP | disclosed |
| US-4327176-A | IMPACT RESISTANT ACRYLIC ESTER RESIN BINDER | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1982-04-27 | — | — | US | disclosed |
| US-4268626-A | Dry image forming material | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1981-05-19 | — | — | US | disclosed |
| US-4234679-A | ORGANIC SILVER SALT, SILVER HALIDE, REDUCING AGENT, ORGANIC BROMINE COMPOUND | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1980-11-18 | — | — | US | disclosed |
| US-4230644-A | DERIVED FROM TRIARYL PHOSPHITES AND CHLORINE OR BROMINE | ELI LILLY AND COMPANY (US) | 1980-10-28 | — | — | US | disclosed |
| EP-0015079-A1 | Halogenating compounds and a process for their production | ELI LILLY AND COMPANY (US) | 1980-09-03 | — | — | EP | disclosed |
| US-4212937-A | NITROGEN-CONTAINING HETEROCYCLIC BASE | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1980-07-15 | — | — | US | disclosed |
| US-4173482-A | Dry image forming material containing an organic silver salt oxidizing agent, a reducing agent and a halogen molecule | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1979-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034235-A1 | Cyclization method for the synthesis of pyrrolidine derivative compounds | CYCS, PRMT9, PRMT5 | ACHE 4283/4885LTA4H 3430/4885TSHR 123/4885 |
| US-20120046308-A1 | NOVEL ALPHA-PHENOXYBENZENEACETIC ACID DERIVATIVE AND PHARMACEUTICAL PREPARATION COMPRISING SAME | PPARA, PPARG, PPARD | ACHE 3634/4885LTA4H 3136/4885TSHR 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.